The FDA on May 21, 2018 approved DOPTELET® for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure. DOPTELET® is a product of AkaRx Inc.
Bottom Ad
Advertisement
Subscribe
Top Ad
Advertisement
Advertisement
The FDA on May 21, 2018 approved DOPTELET® for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure. DOPTELET® is a product of AkaRx Inc.
Advertisement